Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 7,523 |
|
|||||
| News | - | ||||||
| Day High | 4.59 | Low High |
|||||
| Day Low | 4.47 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Marker Therapeutics Inc | MRKR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.075 | 1.69% | 4.50 | 13:19:28 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.50 | 4.47 | 4.59 | 4.425 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 34 | 7,523 | $ 4.55 | $ 34,249 | - | 0.76 - 9.6799 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:32:51 | 1 | $ 4.43 | USD |
Marker Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 40M | 8.89M | - | 3.31M | -8.24M | -0.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Marker Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRKR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.73 | 4.73 | 4.05 | 4.22 | 13,019 | -0.23 | -4.86% |
| 1 Month | 4.58 | 4.93 | 4.05 | 4.52 | 20,229 | -0.08 | -1.75% |
| 3 Months | 4.36 | 5.00 | 3.40 | 4.32 | 19,331 | 0.14 | 3.21% |
| 6 Months | 2.92 | 6.1568 | 2.40 | 4.43 | 51,421 | 1.58 | 54.11% |
| 1 Year | 0.99 | 9.6799 | 0.76 | 2.66 | 263,136 | 3.51 | 354.55% |
| 3 Years | 23.40 | 36.50 | 0.6706 | 10.52 | 567,519 | -18.90 | -80.77% |
| 5 Years | 52.60 | 91.70 | 0.6706 | 19.39 | 645,626 | -48.10 | -91.44% |
Marker Therapeutics Description
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart. |
